TWST Twist Bioscience Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1581280 · Fiscal year ends 09/30
Financial factors as of 2026-09-30 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY22.0%
TTM net income YoY-67.6%
TTM EPS YoY-60.0%
Revenue 3-yr CAGR23.3%
Net income 3-yr CAGR—
Margins
Gross margin52.4%
Operating margin-30.4%
Net margin-28.3%
FCF margin-19.4%
EBITDA margin-24.7%
Returns
ROE-19.1%
ROA-14.8%
ROIC (approx.)-34.2%
Asset turnover0.52x
Leverage & solvency
Liabilities / assets20.8%
Debt / equity0.00x
Current ratio5.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.32x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue10.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-09-30 | FY20252025-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | $459.43M | $376.57M |
| Cost of revenue | $218.63M | $185.57M |
| Gross profit | $240.80M | $191.00M |
| R&D expense | $71.84M | $80.28M |
| SG&A expense | $301.21M | $246.98M |
| Operating income | -$139.46M | -$136.26M |
| Pretax income | -$129.80M | -$76.95M |
| Income tax | $406,000 | $719,000 |
| Net income | -$130.20M | -$77.67M |
| EBITDA | -$112.97M | -$111.41M |
| EPS (basic) | -2.08 | -1.30 |
| EPS (diluted) | -2.08 | -1.30 |
| Weighted avg. shares (diluted) | 62.62M | 59.81M |
| Balance sheet | ||
| Cash & equivalents | $533.99M | $183.05M |
| Short-term investments | $47.91M | $49.38M |
| Receivables | $70.19M | $57.02M |
| Inventory | $46.41M | $28.31M |
| Current assets | $737.22M | $332.97M |
| PP&E, net | $122.32M | $102.28M |
| Goodwill | $82.19M | $82.19M |
| Intangibles | $34.16M | $13.43M |
| Total assets | $1.12B | $641.86M |
| Current liabilities | $125.81M | $91.41M |
| Total liabilities | $233.79M | $168.90M |
| Shareholders' equity | $888.02M | $472.96M |
| Shares outstanding | 67.81M | 60.63M |
| Cash flow statement | ||
| Operating cash flow | -$41.43M | -$47.63M |
| Capital expenditure | $47.58M | $28.00M |
| Free cash flow | -$89.01M | -$75.63M |
| Investing cash flow | -$53.09M | -$24.76M |
| Financing cash flow | $446.68M | $28.54M |
| Depreciation & amortization | $26.48M | $24.85M |
| Stock-based compensation | $69.86M | $64.46M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.